Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.38 |
| ▸ | MTOR | P42345 | 14/20 | 0.38 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4508182 | 0.99 | PRKCI (0.39) | PRKCIPIK3CAMTORPIK3C2BCCNE2 | |
| Hydrochloric Acid SCHEMBL4518127 | 0.91 | RORC (0.41) | PRKCIPIK3CAMTORPIK3C2BCCNE2 | |
| SCHEMBL4508184 | 0.90 | RAF1 (0.38) | PRKCIPIK3CAMTORPIK3C2BCCNE2 | |
| SCHEMBL390110 | 0.85 | PRKCI (0.43) | PRKCIPIK3CAMTORPIK3C2BCCNE2 | |
| Hydrochloric Acid SCHEMBL4526797 | 0.84 | PIK3CA (0.42) | PRKCIPIK3CAMTORPIK3C2BCCNE2 | |
| SCHEMBL390173 | 0.84 | PRKCI (0.39) | PRKCIPIK3CAMTORPIK3C2BCCNE2 | |
| Hydrochloric Acid SCHEMBL4529967 | 0.83 | PRKCI (0.39) | PRKCIPIK3CAMTORPIK3C2BCCNE2 | |
| SCHEMBL4528853 | 0.82 | PRKCI (0.37) | PRKCIPIK3CAMTORPIK3C2BCCNE2 | |
| SCHEMBL390178 | 0.82 | MPL (0.40) | PRKCIPIK3CAMTORPIK3C2BCCNE2 | |
| SCHEMBL389875 | 0.82 | PRKCI (0.38) | PRKCIPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2004157-B1 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | ARENA PHARM INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2253311-A2 | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7816364-B2 | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-7557112-B2 | Aromatic-ring-fused pyrimidine derivative | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | US | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | PRKCI 2449/4885PIK3CA 1482/4885MTOR 3630/4885 |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | PRKCI 2449/4885PIK3CA 1482/4885MTOR 3630/4885 |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | GPR119, NOD1, IRS1 | PRKCI 2657/4885PIK3CA 158/4885MTOR 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.